Drugs / Isuzinaxib
Isuzinaxib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03694041 | May 2018 → Mar 2019 | — | Aptabio Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05758896 | Dec 2023 → Jul 2026 overdue | acute kidney injury | Aptabio Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04880109 | Oct 2021 → Apr 2022 | COVID-19 | Aptabio Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04534439 | Aug 2020 → Jul 2021 | diabetic kidney disease, type 2 diabetes mellitus | Aptabio Therapeutics, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06962098 Comparator | May 2025 → Jun 2027 expected | diabetic kidney disease | Aptabio Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isuzinaxib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05758896 ↗ |
| Known as | APX-115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04534439 ↗ |
| Known as | EWHA-18278 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650894 ↗ |
| Known as | ISUZINAXIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650894 ↗ |
| Action | Inhibit | “with a pan-NOX inhibitor, APX-115, could effectively suppress platelet activation and thrombus formation” PMID 40183134 ↗ Apr 2025 |
| Modality | Small molecule | “APX-115 is a potent small molecule inhibitor of NADPH-oxidase (Nox) isozymes being developed by Aptabio Therapeutics Inc.” NCT04880109 ↗ |
| Route | Oral | “oral administration of APX-115 400mg capsule once daily for 12 weeks” NCT04534439 ↗ |